Search & Analyze
Popular Searches
Natco Pharma Ltd.
BSE · 30 Oct, 4:01 PM
- ₹15,350.14 Cr
- 13.41
- 27,665
- ₹801.15 - ₹780.00
- ₹1,216.20 - ₹774.00
Natco Pharma Ltd. (NATCOPHARM) share price closed at ₹782.50 on the BSE on Friday, October 30, 2026, down by 0.67% from its of ₹787.75. In that session NATCOPHARM reached a of 801.15 and of 780.00. The for the session was 786.45. The stands at 818.56 and is at 922.43. Looking at , the stock ended the session in Downtrend.
Stock Overview
₹789.35
₹787.75
₹786.45
₹818.56
Price 4.41% below
₹922.43
Price 15.17% below
Peer Comparison
| Name | |||||||||
|---|---|---|---|---|---|---|---|---|---|
SUN PHARMA. SUNPHARMA | 1,778.25 | 38.91 | 4,26,661.74 | 0.90 | 1,995.07 | -36.16% | 16,198.71 | 11.88% | 19.11 |
DIVI'S LAB. DIVISLAB | 9,715.00 | 88.17 | 2,57,902.73 | 0.31 | 902.00 | 65.50% | 3,080.00 | 27.80% | 21.51 |
TORRENT PHAR TORNTPHARM | 4,635.15 | 83.01 | 1,76,306.21 | 0.82 | 534.00 | -9.64% | 4,979.00 | 50.79% | 19.27 |
LAURUSLABS LAURUSLABS | 2,392.00 | 96.46 | 1,29,242.68 | 0.08 | 436.19 | 124.27% | 2,206.37 | 33.44% | 18.20 |
ZYDUSLIFE ZYDUSLIFE | 1,244.00 | 27.50 | 1,24,089.48 | 0.08 | 990.20 | -34.90% | 8,017.00 | 21.96% | 21.39 |
DR.REDDY'S DRREDDY | 1,350.20 | 40.25 | 1,12,698.53 | 0.59 | 913.20 | -31.69% | 8,697.80 | -1.48% | 13.75 |
CIPLA LTD. CIPLA | 1,380.00 | 38.48 | 1,11,488.55 | 0.94 | 851.51 | -37.08% | 7,403.93 | -2.44% | 16.00 |
Natco Pharma Ltd. NATCOPHARM | 782.50 | 13.41 | 15,350.14 | 0.63 | 206.50 | -57.01% | 735.20 | -44.68% | 17.16 |
Quarterly Results
consolidated figures in ₹ Crores · Quarterly
Profit & Loss
consolidated figures in ₹ Crores · Annual
Balance Sheet
consolidated figures in ₹ Crores
Cash Flow
consolidated figures in ₹ Crores
Ratios
Valuation
Profitability
Leverage & Liquidity
Returns
Mutual Funds Invested(84)
Based on each fund's latest monthly portfolio · Sep 2026
A total of 20 active funds hold 1.58% in Natco Pharma Ltd., contributing to ₹256 Cr of holdings
Corporate Actions
Insider Trading
Sector Overview
Natco Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.
Company Profile
Corporate information and contact details
Company Information
Industry
Pharmaceuticals & Drugs
Founded
1981
Headquarters
Hyderabad, Telangana
Group
Natco
Chairman
V C Nannapaneni
Managing Director
V C Nannapaneni
Company Secretary
Chekuri Venkat Ramesh
Face Value
₹2
CIN
L24230TG1981PLC003201
Get in Touch
Key Management
11 members across the board and senior leadership
Chekuri Venkat Ramesh
Company Secretary & Compliance Officer
—
V C Nannapaneni
Chairman & Managing Director
₹7.60 Cr
Mar '26
Rajeev Nannapaneni
Vice Chairman & CEO
₹7.39 Cr
Mar '26
ADM Chavali
Non Executive Independent Director
₹13.00 L
Mar '26
Lakshminarayana Bolisetty
Non Executive Independent Director
₹13.00 L
Mar '26
Kantipudi Suma
Non Executive Independent Director
₹11.00 L
Mar '26
ADM Chavali
Non Executive Independent Director
₹6.80 L
Mar '25
Nitin Jain
Non Executive Independent Director
₹10.50 L
Mar '26
Dronadula Vijaya Bhaskar
Non Executive Independent Director
₹15.00 L
Mar '26
D Linga Rao
Whole Time Director - Technical
₹2.17 Cr
Mar '26
PSRK Prasad
Whole Time Director - Corporate Engineering Services
₹2.17 Cr
Mar '26
NATCOPHARM Latest News
News
10 of 10 articlesNATCO Pharma informs about disclosure
NATCO Pharma soars on launching Carboplatin Injection
The company launches this product in manufacturing collaboration with Teyro Labs, based in Chennai
NATCO Pharma launches Carboplatin Injection
The company has launched this product in manufacturing collaboration with Teyro Labs
Natco Pharma informs about board meeting
NATCO Pharma moves up on investing $14 million in eGenesis
The total investment made by NATCO Pharma in eGenesis, Inc. now stands at $22 million
NATCO Pharma investing $14 million in eGenesis
The total investment made by NATCO Pharma in eGenesis, Inc. now stands at $22 million
NATCO Pharma submits investor presentation
Natco Pharma soars on getting USFDA's tentative approval for Olaparib tablets
NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S
Natco Pharma gets USFDA's tentative approval for Olaparib tablets
NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S
Natco Pharma informs about press release